|
시장보고서
상품코드
2054820
췌장암 치료 및 진단 시장 : 종류별, 지역별Pancreatic Cancer Therapeutics and Diagnostic Market, By Type (Treatment (Targeted Therapies, Chemotherapy, Surgery, and Other Treatments), By Geography (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America)) |
||||||
췌장암 치료 및 진단 시장은 2026년에 39억 6,630만 달러로 추정되며, 2033년까지 65억 8,030만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 7.5%로 성장할 것으로 전망됩니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2025년 | 시장 규모(2026년) | 39억 6,630만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간 CAGR(2026-2033년) | 7.50% | 예측 금액(2033년) | 65억 8,030만 달러 |
췌장암은 췌장 세포에서 발생하는 암의 일종입니다. 췌장암은 췌장 세포에 변화(변이)가 생겨 세포가 통제 불능 상태로 증식함으로써 발병합니다. 이 암은 초음파 검사, 컴퓨터 단층촬영(CT), 자기공명영상(MRI), 양전자 방출 단층촬영(PET) 등을 통해 진단됩니다. 치료법으로는 수술, 방사선 치료, 화학요법, 또는 이들을 병용한 치료 등이 있습니다.
시장 역학:
췌장암 발병률 및 유병률의 증가, 신규 치료제 개발 확대, 고령 인구 증가, 안전하고 효과적인 치료제에 대한 수요 증가, 그리고 대중의 인식 제고 등이 전 세계 췌장암 치료 및 진단 시장의 성장을 촉진할 것으로 예상되는 주요 요인입니다.
예를 들어, 2022년 1월, Myriad Genetics Inc.와 Illumina Inc.는 국제 시장을 겨냥한 키트 형태의 myChoice 동반진단 검사를 개발하기 위해 제휴를 맺었습니다. 이 검사는 췌장암을 발견하는 데 사용할 수 있습니다.
또한, 2021년 9월에는 인도 의학 연구 위원회(ICMR) 산하 국립 암 예방·연구 연구소(NICPR)가 'India against Cancer(암에 맞서는 인도)'를 주제로 'www.cancerindia.org'를 출범시켰습니다. 이 포털 사이트는 췌장암을 포함한 암에 대한 인식 제고, 예방 및 치료에 중점을 두고, 인도 내 주요 암에 관한 정보를 제공하고 있습니다.
본 보고서의 주요 특징
- 본 보고서는 각 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안에 대한 매트릭스를 설명하고 있습니다.
- 또한 시장의 촉진요인 및 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 관한 중요한 분석도 제공하고 있습니다.
- 전 세계 췌장암 치료 및 진단 시장의 주요 기업 개요을 다양한 지표(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등)를 바탕으로 소개합니다.
- 본 보고서의 인사이트를 바탕으로, 마케팅 담당자와 기업 경영진은 향후 제품 출시, 제품 라인업 개편, 시장 확대 및 마케팅 전략에 관해 충분한 정보를 바탕으로 의사결정을 내릴 수 있습니다.
- '세계 췌장암 치료 및 진단 시장' 보고서는 투자자, 공급업체, 제품 제조사, 유통업체, 신규 진입자, 재무 분석가 등 이 업계의 다양한 이해관계자들을 대상으로 합니다.
- 이해관계자들은 전 세계 췌장암 치료 및 진단 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 의사결정을 보다 수월하게 할 수 있습니다.
목차
제1장 분석 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 췌장암 치료 및 진단 시장 : 종류별(2021-2033년)
제5장 세계의 췌장암 치료 및 진단 시장 : 지역별(2021-2033년)
제6장 경쟁 구도
제7장 섹션
KSM 26.06.18Pancreatic Cancer Therapeutics And Diagnostic Market is estimated to be valued at USD 3,966.3 Mn in 2026 and is expected to reach USD 6,580.3 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.5% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 3,966.3 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.50% | 2033 Value Projection: | USD 6,580.3 Mn |
Pancreatic cancer is cancer that forms in the cells of the pancreas. Pancreatic cancer occurs when changes (mutations) in the pancreas cells lead them to multiply out of control. The cancer can be diagnosed with the help of ultrasound, computerized tomography (CT) scans, magnetic resonance imaging (MRI) and positron emission tomography (PET) scans. Treatment may include surgery, radiation, chemotherapy, or a combination of these.
Market Dynamics:
Rise in incidence and prevalence of pancreatic cancer, rise in development of novel therapeutics, growing geriatric population, increase in demand for safe and effective therapeutics, and increase in awareness among people are major factors expected to augment growth of the global pancreatic cancer therapeutics and diagnostic market.
For instance, in January 2022, Myriad Genetics Inc. and Illumina Inc. collaborated to develop a kit-based version of the myChoice companion diagnostic test for international markets, which can be used to detect pancreatic cancer.
Moreover, in September 2021, the Indian Council of Medical Research (ICMR)-National Institute of Cancer Prevention and Research (NICPR) launched www.cancerindia.org with the theme 'India against Cancer, a portal that provides information on the leading cancers in India with the major focus on awareness, prevention, and treatment of cancers, including pancreatic cancer.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global pancreatic cancer therapeutics and diagnostic market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include F Hoffmann-La Roche AG, Merck KgaA, Apexigen Inc., Immunovia AB, Viatris Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb, Novartis AG, Pfizer Inc., Myriad Genetics Inc., Canon Medical Systems Corporation, FUJIFILM Holdings Corporation, Boston Scientific Corporation, and Rafael Holdings Inc. (Rafael Pharmaceuticals), among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global pancreatic cancer therapeutics and diagnostic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pancreatic cancer therapeutics and diagnostic market.
Detailed Segmentation:
- Global Pancreatic Cancer Therapeutics and Diagnostic Market, By Type (Revenue, USD Mn, 2021 - 2033)
- Treatment
- Diagnostics
- Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles:
- F.Hoffmann-La Roche AG
- Merck KgaA
- Apexigen Inc.
- Immunovia AB
- Viatris Inc.
- Amgen Inc.
- AstraZeneca PLC
- Bristol-Myers Squibb
- Novartis AG
- Pfizer Inc.
- Myriad Genetics Inc.
- Canon Medical Systems Corporation
- FUJIFILM Holdings Corporation
- Boston Scientific Corporation
- Rafael Holdings Inc. (Rafael Pharmaceuticals)
Table of Contents:
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Geography
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Rise in incidence and prevalence of pancreatic cancer
- High cost associated with diagnosis and treatments
- Increase in demand for safe and effective therapeutics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Pancreatic Cancer Therapeutics and Diagnostic Market, By Type, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Diagnostics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
5. Global Pancreatic Cancer Therapeutics and Diagnostic Market, By Geography, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(USD Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(USD Mn)
- GCC Country
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(USD Mn)
- South Africa
- North Africa
- Central Africa
6. Competitive Landscape
- F. Hoffmann-La Roche AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck KgaA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Apexigen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Immunovia AB
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Myriad Genetics Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Canon Medical Systems Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- FUJIFILM Holdings Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Boston Scientific Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Rafael Holdings Inc. (Rafael Pharmaceuticals)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Analyst Views
7. Section
- Research Methodology
- About us
